arrow
P

Pablo Mandó

centro de educación médica e investigaciones clínica (cemic), buenos aires, argentina
H指数:10
被引数:370

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey

年轻患者激素受体阳性、HER2阴性早期乳腺癌的医师治疗决策:一项拉丁美洲调查

2025-10-150
OA
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

风险降低手术与年轻BRCA携带者乳腺癌患者生存期的关联:一项国际队列研究

2025-05-080
PRE
Determining Clinicopathologic Factors That Influence Treatment in Advanced Breast Cancer in Argentina After CDK4/6 Inhibitors
2024-09-010
OA
Immune-mediated secondary adrenal insufficiency is more commonly found in younger patients undergoing neoadjuvant treatment for early breast cancer

免疫介导的继发性肾上腺功能不全在年轻早期乳腺癌接受新辅助治疗的患者的发生率更高。

2024-09-010
PRE
Cyclin-dependent kinase inhibitor plus endocrine therapy in HR+/HER2-invasive breast cancer with bone marrow and pancytopenia: a new standard of care? Collaborative multicentric Argentinean real-world study (SUMA-02)
2024-05-020
PRE
LuciA-15-A real-world prospective study of PARP inhibitors for the treatment of Latin American patients with HER-2 negative metastatic breast cancer with mutation of BRCA1/2 genes or in the Homologous Recombination Repair genes
2024-05-020
PRE
Young oncologists' perspective on the role and future of the clinician-scientist in oncology
2023-10-013
OAAI
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
2020-09-0122
PREAI